High adherence to prophylaxis regimens in haemophilia B patients receiving rIX-FP: Evidence from clinical trials and real-world practice. [PDF]
Haemophilia, 2020 Adherence to prophylaxis regimens is essential for bleed prevention in haemophilia but remains a challenge due to the need for frequent infusions.
Mancuso ME +7 more
europepmc +3 more sources
Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years. [PDF]
Haemophilia, 2020 In clinical trials, recombinant factor IX fusion protein (rFIXFc) has demonstrated safety, efficacy and prolonged activity with extended dosing intervals for treatment of haemophilia B.
Shapiro A +8 more
europepmc +4 more sources
Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B. [PDF]
Haemophilia, 2019 Bleeding severity in haemophilia usually correlates with the lev‐ els of circulating clotting factor.1 Patients with mild (factor levels 6%‐40% of normal activity) or moderate haemophilia (1%‐5%) bleed infrequently, predominantly due to trauma or after ...
Gill JC, Roberts J, Li Y, Castaman G.
europepmc +4 more sources
Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B. [PDF]
Haemophilia, 2019 In 2010, nonacog alfa became the first recombinant factor IX (rFIX) available in Japan for patients with haemophilia B.
Fukutake K +6 more
europepmc +4 more sources
Association of factor expression levels with annual bleeding rate in people with haemophilia B. [PDF]
Haemophilia, 2023 Gene therapy clinical trials measure steady‐state clotting factor expression levels (FELs) to evaluate the modulation of the bleeding phenotype, aiming to offer consistent protection against breakthrough bleeding events.
Burke T +8 more
europepmc +2 more sources
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) - Unmet needs remain. [PDF]
Haemophilia, 2022 The B‐Natural study is a multicentre, multinational, observational study of haemophilia B (HB) designed to increase understanding of clinical manifestations, treatment and quality of life (QoL).
Berntorp E +27 more
europepmc +2 more sources
IDEAL study: A real-world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in Italy. [PDF]
Haemophilia, 2023 Factor IX replacement therapy is used for treatment and prophylaxis of bleeding in haemophilia B. rIX‐FP is an extended half‐life albumin‐fusion protein, which, in clinical studies, has demonstrated prolonged dosing intervals up to 21 days for routine ...
Tagliaferri A +27 more
europepmc +2 more sources
Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B. [PDF]
Haemophilia, 2021 Phase 2b study to assess efficacy, safety, thrombogenicity, immunogenicity and tolerability with 28 days of daily dosing of subcutaneous (SQ) dalcinonacog alfa as prophylaxis for haemophilia B (HB).
Mahlangu J, Levy H, Lee M, Del Greco F.
europepmc +2 more sources
International consensus recommendations on the management of people with haemophilia B [PDF]
Therapeutic Advances in Hematology, 2022 Haemophilia B is a rare X-linked genetic deficiency of coagulation factor IX (FIX) that, if untreated, can cause recurrent and disabling bleeding, potentially leading to severe arthropathy and/or life-threatening haemorrhage.
Daniel P. Hart +14 more
doaj +2 more sources
Haemophilia specialist nurses’ perceptions of haemophilia B
The Journal of Haemophilia Practice, 2021 Some clinicians believe that haemophilia B is associated with less bleeding than haemophilia A, yet there appears to be little difference in health-related outcomes.
Chaplin Steve +9 more
doaj +2 more sources